400 related articles for article (PubMed ID: 19772941)
1. Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.
Lo JC; O'Ryan FS; Gordon NP; Yang J; Hui RL; Martin D; Hutchinson M; Lathon PV; Sanchez G; Silver P; Chandra M; McCloskey CA; Staffa JA; Willy M; Selby JV; Go AS;
J Oral Maxillofac Surg; 2010 Feb; 68(2):243-53. PubMed ID: 19772941
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
Murad OM; Arora S; Farag AF; Guber HA
Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
[TBL] [Abstract][Full Text] [Related]
3. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
4. Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.
O'Ryan FS; Khoury S; Liao W; Han MM; Hui RL; Baer D; Martin D; Liberty D; Lo JC
J Oral Maxillofac Surg; 2009 Jul; 67(7):1363-72. PubMed ID: 19531404
[TBL] [Abstract][Full Text] [Related]
5. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.
Mavrokokki T; Cheng A; Stein B; Goss A
J Oral Maxillofac Surg; 2007 Mar; 65(3):415-23. PubMed ID: 17307586
[TBL] [Abstract][Full Text] [Related]
6. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Kunchur R; Need A; Hughes T; Goss A
J Oral Maxillofac Surg; 2009 Jun; 67(6):1167-73. PubMed ID: 19446200
[TBL] [Abstract][Full Text] [Related]
7. Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry.
Sedghizadeh PP; Stanley K; Caligiuri M; Hofkes S; Lowry B; Shuler CF
J Am Dent Assoc; 2009 Jan; 140(1):61-6. PubMed ID: 19119168
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
9. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices.
Fugazzotto PA; Lightfoot WS; Jaffin R; Kumar A
J Periodontol; 2007 Sep; 78(9):1664-9. PubMed ID: 17760533
[TBL] [Abstract][Full Text] [Related]
10. [Osteonecrosis of the jaw developing during bisphosphonate treatment].
Udvardy E; Redl P; Márton I
Magy Onkol; 2008 Mar; 52(1):81-7. PubMed ID: 18403302
[TBL] [Abstract][Full Text] [Related]
11. Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate.
Ulmner M; Jarnbring F; Törring O
J Oral Maxillofac Surg; 2014 Jan; 72(1):76-82. PubMed ID: 23992777
[TBL] [Abstract][Full Text] [Related]
12. Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN.
Barasch A; Cunha-Cruz J; Curro FA; Hujoel P; Sung AH; Vena D; Voinea-Griffin AE; ; Beadnell S; Craig RG; DeRouen T; Desaranayake A; Gilbert A; Gilbert GH; Goldberg K; Hauley R; Hashimoto M; Holmes J; Latzke B; Leroux B; Lindblad A; Richman J; Safford M; Ship J; Thompson VP; Williams OD; Yin W
J Dent Res; 2011 Apr; 90(4):439-44. PubMed ID: 21317246
[TBL] [Abstract][Full Text] [Related]
13. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.
Khan AA; Sándor GK; Dore E; Morrison AD; Alsahli M; Amin F; Peters E; Hanley DA; Chaudry SR; Dempster DW; Glorieux FH; Neville AJ; Talwar RM; Clokie CM; Al Mardini M; Paul T; Khosla S; Josse RG; Sutherland S; Lam DK; Carmichael RP; Blanas N; Kendler D; Petak S; St-Marie LG; Brown J; Evans AW; Rios L; Compston JE;
J Rheumatol; 2008 Jul; 35(7):1391-7. PubMed ID: 18528958
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Vahtsevanos K; Kyrgidis A; Verrou E; Katodritou E; Triaridis S; Andreadis CG; Boukovinas I; Koloutsos GE; Teleioudis Z; Kitikidou K; Paraskevopoulos P; Zervas K; Antoniades K
J Clin Oncol; 2009 Nov; 27(32):5356-62. PubMed ID: 19805682
[TBL] [Abstract][Full Text] [Related]
15. Importance of microcracks in etiology of bisphosphonate-related osteonecrosis of the jaw: a possible pathogenetic model of symptomatic and non-symptomatic osteonecrosis of the jaw based on scanning electron microscopy findings.
Hoefert S; Schmitz I; Tannapfel A; Eufinger H
Clin Oral Investig; 2010 Jun; 14(3):271-84. PubMed ID: 19536569
[TBL] [Abstract][Full Text] [Related]
16. Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates.
Gebara SN; Moubayed H
Am J Health Syst Pharm; 2009 Sep; 66(17):1541-7. PubMed ID: 19710437
[TBL] [Abstract][Full Text] [Related]
17. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
18. [Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Barrier A; Lescaille G; Rigolet A; Descroix V; Goudot P; Ruhin B
Rev Stomatol Chir Maxillofac; 2010 Sep; 111(4):196-202. PubMed ID: 20810140
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.
Van Poznak C; Estilo C
Oncology (Williston Park); 2006 Aug; 20(9):1053-62; discussion 1065-6. PubMed ID: 16986349
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies.
Boonyapakorn T; Schirmer I; Reichart PA; Sturm I; Massenkeil G
Oral Oncol; 2008 Sep; 44(9):857-69. PubMed ID: 18282788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
